PCA
JAZZ icon

Private Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Private Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,225
Closed -$4.07M – 95
2018
Q3 		$4.07M Buy
24,225
+25
+0.1% +$4.3K 1.12% 34
2018
Q2 		$4.17M Buy
+24,200
New +$3.96M 1.31% 32

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Private Capital Advisors's JAZZ Position: Q4 2018 in Review

Private Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 24,225 shares — an estimated $4.07M sold.

Private Capital Advisors first reported a position in JAZZ in Q2 2018 and held it in 2 quarters. The position peaked at $4.17M in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Private Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Private Capital Advisors sold 24,225 Jazz Pharmaceuticals shares in Q4 2018, an estimated $4.07M.
  • Private Capital Advisors first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Private Capital Advisors's Jazz Pharmaceuticals position peaked at $4.17M in Q2 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Private Capital Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.